Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Tap an ingredient for the detail: Ksm-66Cytochrome P450 1a2 (cyp1a2) Substrates, Hepatotoxic Drugs Moderate Interaction Summary Theoretically, ashwagandha might decrease the levels and clinical effects of CYP1A2 substrates
Side effects that are most common can include: Reduced appetite Burping Constipation Diarrhoea Dizziness Fatigue Gastrointestinal discomfort Gastrointestinal disorders Hypoglycaemia (when used in combination with insulin or sulfonylureas) Nausea Vomiting Reduced body weight Other less common side effects that can be experienced may include pancreatitis and altered taste
Inflammation induces angiogenesis at lesion site and simultaneously promotes rapid synovial sites growth through capillary-derived nutrition [82]
Connect with an APC Team Member: Reporter's Inquiry Form Tell FDA: Nonsense
Start your evaluation
US$ 25.10
US$ 20.90
US$ 27.48
US$ 20.32
US$ 26.92
